AI Articles and Analysis in Healthcare

Diabetes is a leading chronic disease that affects more than 30 million people in the United States. The disease results from high blood glucose (blood sugar) due to an inability to properly derive energy from food, primarily in the form of glucose. Insulin is a hormone that normally helps process glucose in the body. However, in the case of diabetes, insulin is inadequate (Type 2 diabetes) or obsolete (Type 1 diabetes).

Episode Summary: This week’s episode covers the medical applications of machine vision for the diagnosis and treatment of cancer. Medical science has integrated AI since the late 90s, and it’s been useful in the fight against cancer. This week’s guest is Dr. Alexandre Le Bouthillier, founder of Imagia. Imagia is a medical imaging company which specializes in using AI and machine learning to detect cancer in its early stages so that oncologists can make quicker, more accurate diagnoses for patients.

Medical devices sector, part of the $3 trillion healthcare industry in the United States, is an area of growth and innovation where researchers and manufacturers are seeking to integrate accuracy with automation. According to the most recent data reported by SelectUSA, (a program within the International Trade Administration at the U.S. Department of Commerce), the United States held 40 percent of the $140 billion global medical device market in 2015.

The healthcare analytics market continues to gain traction as the healthcare industry transitions to a value-based care model. Value-based care focuses on quality of care delivery as opposed to volume of patients served. There are great opportunities for data analytics due to the high volume of information that must be routinely collected, tracked and interpreted, particularly in the hospital setting. Examples of value-based care programs in the hospital setting include the Hospital Value-Based Purchasing (HVBP) Program and the Hospital Readmission Reduction (HRR) Program.

Gunjan Bhardwaj is the Founder and CEO of Innoplexus, a leader in AI, machine learning, and analytics as a service for healthcare, pharma, and the life sciences. He was earlier with the Boston Consulting Group and before that the leader of the global business performance think-tank of Ernst & Young and a manager in the German practice with a solution focus on strategy and innovation.

Episode Summary: This episode explores the ways in which artificial intelligence has the potential to revolutionize the field of medicine. This week's guest, Turbine.ai's Dr. Kristóf Zsolt Szalay speaks to this topic, discussing research that hopes to create automated learning networks and algorithms designed to predict the development of human cells in response to drugs. This technological innovation would make it possible for near-instantaneous simulations to be run, allowing optimal combinations and optimal doses of drugs to be pinpointed and distributed to patients.

The application of robotics in surgery has steadily grown since it began in the 1980s. In contrast, the integration of artificial intelligence in this sector is still fairly new. As promising applications, predominantly in the research and development phase, begin to the surface we aim to answer the important questions that business leaders are asking today:

Episode summary: In this episode, we talk to Murali Aravamudan, Founder and CEO of AI-driven drug discovery startup Qrativ, a joint venture by the Mayo Clinic and biotech/data science firm nference. Murali and I discuss the surge of medical information and data in the medical industry, the role of artificial intelligence in developing drugs for treatments to various diseases, and the future of AI in drug discovery.